149323-50-2

Basic information

• Product Name: 5-Bromo-4-(4-methylphenyl)pyrimidine
• Synonyms: 5-Bromo-4-(4-methylphenyl)pyrimidine;5-Bromo-4-p-tolylpyrimidine
• CAS NO: 149323-50-2
• Molecular Formula: C₁₁H₉BrN₂
• Molecular Weight: 249.11
• Product Categories: blocks;Bromides
• Mol File: 149323-50-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 343.1°Cat760mmHg
• Flash Point: 161.3°C
• Appearance: /
• Density: 1.434g/cm³
• Vapor Pressure: 0.000143mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: 2-8°C
• PKA: 0.47±0.16(Predicted)
• CAS DataBase Reference: 5-Bromo-4-(4-methylphenyl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-4-(4-methylphenyl)pyrimidine(149323-50-2)
• EPA Substance Registry System: 5-Bromo-4-(4-methylphenyl)pyrimidine(149323-50-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 149323-50-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-4-(4-methylphenyl)pyrimidine, also known as 5-Bromo-4-(p-tolyl)pyrimidine, is a chemical compound with the molecular formula C11H9BrN2. It is a pyrimidine derivative that contains a bromine atom and a p-tolyl group attached to the pyrimidine ring. 5-Bromo-4-(4-methylphenyl)pyrimidine has applications in the pharmaceutical industry, specifically in the synthesis of various pharmaceuticals and drug intermediates. It is also used in scientific research as a building block for the synthesis of diverse organic compounds. 5-Bromo-4-(4-methylphenyl)pyrimidine is known for its role in various chemical reactions and is sought after for its versatility in organic synthesis.

InChI:InChI=1/C11H9BrN2/c1-8-2-4-9(5-3-8)11-10(12)6-13-7-14-11/h2-7H,1H3

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 106-38-7 para-bromotoluene 

Downstream Products

• 149323-51-3 5-cyano-4-(p-tolyl)pyrimidine 

Relevant articles and documents

FUSED HETEROCYCLIC COMPOUNDS, HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY

Fused heterocyclic compounds of the formula (I): STR1 wherein R. sup.1 is an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R 2 is a group capable of forming an anion or a group convertible thereinto; R 3 is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X is a direct bond or a spacer having an atomic length of two or less between the R 3 group and the ring W group; W is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hereto atom; a,c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom wherein one of b or e must be nitrogen; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R 1, the following group: STR2 may form a ring group; provided that when STR3 is a benzimidazole, thieno[3,4-d] imidazole, or thieno[2,3-d] imidazole ring, at least one of the group: STR4 and R 3 is an optionally substituted heterocyclic residue; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.